Replimune Group (NASDAQ:REPL) Shares Down 7.6% – Should You Sell?

Shares of Replimune Group, Inc. (NASDAQ:REPL) traded down 7.6% on Monday . The company traded as low as $9.63 and last traded at $9.60. 342,987 shares traded hands during trading, a decline of 52% from the average session volume of 712,642 shares. The stock had previously closed at $10.39.

Analyst Ratings Changes

Several analysts recently weighed in on the stock. HC Wainwright raised their target price on shares of Replimune Group from $21.00 to $22.00 and gave the company a “buy” rating in a report on Thursday, February 13th. Jefferies Financial Group lifted their price objective on shares of Replimune Group from $16.00 to $19.00 and gave the stock a “buy” rating in a research report on Wednesday, December 4th. JPMorgan Chase & Co. increased their target price on Replimune Group from $16.00 to $18.00 and gave the company an “overweight” rating in a report on Wednesday, February 26th. Finally, BMO Capital Markets lifted their price target on Replimune Group from $18.00 to $27.00 and gave the stock an “outperform” rating in a report on Wednesday, January 22nd. Seven equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $19.43.

Replimune Group Stock Down 6.2 %

The firm’s 50 day simple moving average is $12.67 and its 200-day simple moving average is $12.17. The company has a market cap of $750.90 million, a price-to-earnings ratio of -3.18 and a beta of 1.30. The company has a debt-to-equity ratio of 0.14, a current ratio of 11.43 and a quick ratio of 11.43.

Replimune Group (NASDAQ:REPL) last announced its earnings results on Wednesday, February 12th. The company reported ($0.79) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.70) by ($0.09). As a group, sell-side analysts anticipate that Replimune Group, Inc. will post -2.97 earnings per share for the current year.

Hedge Funds Weigh In On Replimune Group

A number of institutional investors have recently modified their holdings of REPL. Wellington Management Group LLP grew its position in Replimune Group by 352.5% during the 4th quarter. Wellington Management Group LLP now owns 1,096,744 shares of the company’s stock worth $13,282,000 after purchasing an additional 854,346 shares during the last quarter. California State Teachers Retirement System boosted its stake in shares of Replimune Group by 25.9% during the fourth quarter. California State Teachers Retirement System now owns 42,725 shares of the company’s stock worth $517,000 after buying an additional 8,793 shares during the period. Woodline Partners LP grew its holdings in shares of Replimune Group by 156.6% during the fourth quarter. Woodline Partners LP now owns 854,309 shares of the company’s stock worth $10,346,000 after buying an additional 521,366 shares during the last quarter. Velan Capital Investment Management LP acquired a new stake in shares of Replimune Group in the 4th quarter worth $2,196,000. Finally, Soleus Capital Management L.P. acquired a new stake in shares of Replimune Group in the 4th quarter worth $3,179,000. 92.53% of the stock is owned by institutional investors and hedge funds.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.